Endo International PLC (NASDAQ:ENDP)’s share price gapped up prior to trading on Wednesday . The stock had previously closed at $17.32, but opened at $17.39. Endo International PLC shares last traded at $17.61, with a volume of 4,421,158 shares changing hands.

A number of equities analysts have issued reports on ENDP shares. Royal Bank Of Canada lowered Endo International PLC from a “top pick” rating to an “outperform” rating and cut their target price for the company from $73.00 to $47.00 in a research report on Friday, March 18th. William Blair reaffirmed a “hold” rating and issued a $35.00 target price on shares of Endo International PLC in a research report on Friday, March 18th. Deutsche Bank AG cut their target price on Endo International PLC from $70.00 to $68.00 and set a “buy” rating on the stock in a research report on Friday, March 18th. Nomura Holdings Inc. reaffirmed a “buy” rating and issued a $80.00 target price on shares of Endo International PLC in a research report on Monday, March 21st. Finally, JPMorgan Chase & Co. cut their target price on Endo International PLC from $80.00 to $65.00 and set an “overweight” rating on the stock in a research report on Monday, March 21st. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have assigned a buy rating to the company. Endo International PLC currently has a consensus rating of “Hold” and an average price target of $40.32.

The stock’s market capitalization is $3.87 billion. The firm’s 50-day moving average is $16.51 and its 200 day moving average is $33.52.

Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings data on Thursday, May 5th. The company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.04 by $0.04. The firm had revenue of $963.54 million for the quarter, compared to analyst estimates of $960.96 million. During the same period in the previous year, the business posted $1.17 EPS. Endo International PLC’s revenue for the quarter was up 34.9% compared to the same quarter last year. Equities analysts forecast that Endo International PLC will post $4.56 EPS for the current fiscal year.

In related news, insider Paul Campanelli bought 13,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The stock was acquired at an average price of $15.53 per share, for a total transaction of $201,890.00. Following the transaction, the insider now directly owns 201,069 shares of the company’s stock, valued at $3,122,601.57. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arthur J. Higgins bought 11,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 10th. The shares were bought at an average price of $15.42 per share, with a total value of $169,620.00. Following the transaction, the director now directly owns 45,623 shares in the company, valued at $703,506.66. The disclosure for this purchase can be found here.

Several institutional investors recently bought and sold shares of ENDP. Cibc World Markets Corp bought a new position in Endo International PLC during the fourth quarter valued at approximately $47,081,000. New York State Common Retirement Fund increased its position in shares of Endo International PLC by 7.8% in the fourth quarter. New York State Common Retirement Fund now owns 517,200 shares of the company’s stock valued at $31,663,000 after buying an additional 37,500 shares during the last quarter. Mcclain Value Management LLC increased its position in shares of Endo International PLC by 45.6% in the fourth quarter. Mcclain Value Management LLC now owns 334,302 shares of the company’s stock valued at $20,466,000 after buying an additional 104,705 shares during the last quarter. BNP Paribas Arbitrage SA increased its position in shares of Endo International PLC by 4.7% in the fourth quarter. BNP Paribas Arbitrage SA now owns 273,393 shares of the company’s stock valued at $16,737,000 after buying an additional 12,234 shares during the last quarter. Finally, Quantitative Investment Management LLC acquired a new position in shares of Endo International PLC during the fourth quarter valued at about $2,650,000.

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.